logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Tag: Ablynx (ABLX)

Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

VERTEX From Europe,  Vertex (VRTX)  was informed that the European Commission has granted an extension of the Marketing Authorization for  ORKAMBI ®   (lumacaftor/ivacaftor). Orkambi is for cystic fibrosis (CF) in people with two copies of the  F508del  mutation, including...

Read More

January 11, 2018

0

Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

VERTEX From Europe,  Vertex (VRTX)  was informed that the European Commission has granted an extension of the Marketing Authorization for  ORKAMBI ®   (lumacaftor/ivacaftor). Orkambi is for cystic fibrosis (CF) in people with two copies of the  F508del  mutation, including...

Read More

January 11, 2018

0

Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

VERTEX From Europe,  Vertex (VRTX)  was informed that the European Commission has granted an extension of the Marketing Authorization for  ORKAMBI ®   (lumacaftor/ivacaftor). Orkambi is for cystic fibrosis (CF) in people with two copies of the  F508del  mutation, including...

Read More

January 11, 2018

0

  • 1

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy